A SEQUENTIAL STUDY OF INTRAVENOUS AND ORAL FLEROXACIN FOR 7 OR 14 DAYS IN THE TREATMENT OF COMPLICATED URINARY-TRACT INFECTIONS

Citation
R. Degier et al., A SEQUENTIAL STUDY OF INTRAVENOUS AND ORAL FLEROXACIN FOR 7 OR 14 DAYS IN THE TREATMENT OF COMPLICATED URINARY-TRACT INFECTIONS, International journal of antimicrobial agents, 6(1), 1995, pp. 27-30
Citations number
19
Categorie Soggetti
Microbiology,Immunology
ISSN journal
09248579
Volume
6
Issue
1
Year of publication
1995
Pages
27 - 30
Database
ISI
SICI code
0924-8579(1995)6:1<27:ASSOIA>2.0.ZU;2-3
Abstract
Objective: To compare 1 and 2-weeks of sequential intravenous and oral treatment for complicated urinary tract infection. Design: Randomized , clinical trial. Setting: 2 secondary and 1 tertiary care hospital in the Netherlands. Patients. Patients (54) were randomly assigned, afte r 3 days Fleroxacin 400 mg iv once daily, to receive oral fleroxacin ( 400 mg OD,) either during 4 (total 7) days (n = 26), or during 11 (tot al 14) days (n = 28). Thirty-four patients were evaluable for efficacy . Complicated urinary tract infection was defined as the presence of a n anatomical or functional abnormality of the urinary tract, urinary t ract instrumentation, patients presenting with clinical signs and symp toms of pyelonephritis or a serious illness such as diabetes mellitus, immunosuppression or renal failure. Complicated urinary tract infecti on was defined as the presence of an anatomical or functional abnormal ity of the urinary tract, urinary tract instrumentation, patients pres enting with clinical signs and symptoms of pyelonephritis or a serious illness such as diabetes mellitus, immunosuppression or renal failure . Results: A bacteriological cure was seen in 22 of 34 (65%) patients at 4-6 weeks after therapy. Overall, a favorable bacteriological respo nse was obtained in 26 of 34 (76%) patients. No significant difference could be found among the two dosage groups (7 days: 14/18 = 78%; 14 d ays: 12/16 = 75%). Conclusions. Sequential iv and oral treatment with fleroxacin in complicated UTI is a satisfactory treatment modality. La rger trials should be done in a more homogeneous population, studying shorter treatment durations in complicated UTI.